A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).

Tomonori YamanishiHirotaka AsakuraNarihito SekiShoji Tokunaga

Published in: Lower urinary tract symptoms (2018)

For BPH patients with PVR ≥30 mL and remaining storage symptoms despite tamsulosin monotherapy, TDI treatment showed better results in terms of improved OAB symptoms than TD treatment up to 52 weeks.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
open label
double blind
combination therapy
sleep quality
randomized controlled trial
clinical trial
depressive symptoms
phase iii
study protocol